Frederick Raal to Clinical Trials, Phase III as Topic
This is a "connection" page, showing publications Frederick Raal has written about Clinical Trials, Phase III as Topic.
Connection Strength
0,617
-
Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. J Am Coll Cardiol. 2021 03 09; 77(9):1182-1193.
Score: 0,186
-
Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia. Cardiovasc Drugs Ther. 2019 02; 33(1):69-76.
Score: 0,160
-
Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. Lancet Diabetes Endocrinol. 2016 05; 4(5):403-10.
Score: 0,130
-
Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 Phase 3 randomized trials. Diabetes Obes Metab. 2024 Aug; 26(8):3223-3237.
Score: 0,058
-
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2023 01 07; 44(2):129-138.
Score: 0,053
-
Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol. 2015 Mar; 35(3):689-99.
Score: 0,030